WO2011133893A2 - Cyanide antidotes - Google Patents
Cyanide antidotes Download PDFInfo
- Publication number
- WO2011133893A2 WO2011133893A2 PCT/US2011/033619 US2011033619W WO2011133893A2 WO 2011133893 A2 WO2011133893 A2 WO 2011133893A2 US 2011033619 W US2011033619 W US 2011033619W WO 2011133893 A2 WO2011133893 A2 WO 2011133893A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- composition
- sulfanegen
- cyanide
- triethanolamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/08—Six-membered rings
Definitions
- cyanide antidotes must be administered via intravenous (IV) administration.
- Sulfanegen sodium can be an effective cyanide antidote when administered via an intraperitoneal (IP) injection.
- the present invention provides salts of sulfanegen including triethanolamine (TEA), diethanolamine (DEA), monomethylaminoethanol (MMAE) and dimethylaminoethanol (DMAE) salts that are significantly more water soluble than the sodium salt of sulfanegen. Accordingly, these new forms of sulfanegen are useful as cyanide antidotes. These new forms are effective when administered by injection (e.g. , IM or IV or IP) as well as when administered orally, and are inexpensive and rapidly acting, e.g., when administered by IM injection. Brief Description of the Figures
- Figure 1 depicts the effects of sulfanegen TEA 5 min post cyanide exposure.
- Figure 2 depicts the effects of sulfanegen TEA 10 min post cyanide exposure.
- Figure 3 depicts the effects of sulfanegen TEA 20 min post cyanide exposure.
- Figure 4 depicts the effects of sulfanegen TEA 30 min post cyanide exposure.
- Figure 5 depicts the effects of sulfanegen TEA 40 min post cyanide exposure.
- Figure 6 depicts the effects of sulfanegen TEA vs FDA approved antidotes in the mouse model.
- Figure 7 depicts the changes in OxyHb and DeoxyHb in response to cyanide and antidote treatment (IM) in rabbit model.
- Figures 8a and 8b depict the cyanide levels and lactate levels in the swine cyanide models for IM treatment with sulfanegen TEA.
- certain embodiments provide a triethanolamine, diethanolamine, monomethylaminoethanol or dimethylaminoethanol salt of a compound of the formula
- the invention provides a triethanolamine (TEA) or
- X + is TEA or DEA in protonated form.
- X + is triethanolamine, diethanolamine, monomethylaminoethanol or
- the salt is a TEA salt.
- the salt is a DEA salt.
- the salt is a monomethylaminoethanol or dimethylaminoethanol salt.
- X + is melamine, glucosamine, ethanolamine, tromethamine, N-methylaminoethanol and ⁇ , ⁇ -dimethy laminoethanol .
- Certain embodiments provide a pharmaceutical composition
- a pharmaceutical composition comprising a salt as described herein and a pharmaceutically acceptable carrier.
- the composition is adapted for intramuscular (IM)
- the composition is adapted for intravenous (IV) administration. In certain embodiments, the composition is adapted for oral administration.
- the composition is in unit dosage form.
- the composition comprises about 1-10 grams (e.g., about 3-8 grams) of the salt. In certain embodiments, the composition comprises about 1-12 grams of the salt.
- Certain embodiments provide a method of treating cyanide poisoning in a subject in need of such treatment, comprising administering to a subject a therapeutically effective amount of the salt as described herein, or the composition as described herein.
- the salt or composition is administered intramuscularly (IM).
- the salt or composition is administered intravenously (IV).
- the salt or composition is administered orally.
- Certain embodiments provide a salt as described herein for use in therapy.
- Certain embodiments provide a salt as described herein for use in treating cyanide poisoning.
- Certain embodiments provide a salt as described herein for use in medical treatment or diagnosis.
- Certain embodiments provide the use of a salt as described herein to prepare a medicament useful for treating cyanide poisoning in an animal.
- the present salts may be administered, e.g. , IM, IV, or orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.
- a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier.
- the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- Such compositions and preparations should generally contain at least 0.1% of active compound.
- the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form.
- the amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
- the tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
- a liquid carrier such as a vegetable oil or a polyethylene glycol.
- any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non- toxic in the amounts employed.
- the active compound may be incorporated into sustained-release preparations and devices.
- the active compound may also be administered intravenously (IV), intraperitoneally (IP), or intramuscularly (IM) by infusion or injection, e.g., using an autoinjector.
- IV intravenously
- IP intraperitoneally
- IM intramuscularly
- the compounds may be administered using an autoinjector.
- Solutions of the active compound can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
- the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
- the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization.
- the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
- Useful dosages of the compounds can be determined, e.g., by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
- the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
- Compounds of the invention can also be administered in combination with other therapeutic agents, for example, other agents that are useful for the treatment of cyanide exposure. Accordingly, in one embodiment the invention also provides a composition comprising sulfanegen TEA and/or sulfanegen DEA, at least one other therapeutic agent, and a pharmaceutically acceptable diluent or carrier.
- the invention also provides a kit comprising sulfanegen TEA and/or sulfanegen DEA, packaging material, and instructions for administration.
- the kit may also contain at least one other therapeutic agent.
- Scheme 1 illustrates a synthesis that that was used to prepare salts of sulfanegen including compounds of the invention.
- Scheme 1 illustrates the synthesis of salts in the ratio of about 2 : 1 (M + : compound 3).
- the invention also includes other salt ratios, including but not limited to ratios of about 1 : 1.
- the invention also includes other physical forms (e.g.
- the present invention also includes salts of sulfanegen wherein the salt is melamine (4a), glucosamine (4b), ethanolamine (4c), tromethamine (4f), N-methylaminoethanol (4g) and ⁇ , ⁇ -dimethylaminoethanol (4h).
- Scheme 2 depicts the betaine ethyl ester and choline salts of sulfanegen.
- MMAE monomethylaminoethanol
- DMAE dimethylaminoethanol
- the efficacy of cyanide antidotes was measured as follows. A dose less than the LD50 was administered. This causes 'knock-down' or loss of neuromuscular coordination. The efficacy of antidote was measured by reduction in time for the animal to recover neuromuscular coordination. Swiss albino male mice were treated with cyanide (ip) at a dose that requires 60- 70 min for recovery. Briefly, the 'knocked-down' animal was placed on a wire mesh and inverted. The time for the animal to right itself to the top of the wire mesh screen was measured as the recovery time and the antidotal efficacy is measured as the reduction of this recovery time vs. the cyanide alone animals. Statistically this is much more powerful than LD50.
- sulfanegen TEA administered IM or IP
- IM or IP is an effective cyanide antidote
- Figure 6 depicts the effects of sulfanegen TEA vs FDA approved antidotes in the mouse model.
- Figure 7 depicts the changes in OxyHb and DeoxyHb in response to cyanide and antidote treatment (IM) in rabbit model. Rapid recovery was demonstrated in the treated animals.
- Example 4 Toxicity study of sulfanegen salts Sulfanegen-TEA was dissolved in sterile saline and the dose administered in two injections, one in each leg muscle. There were four mice per group and three groups. A high dose of 8.9 mmol/kg (4789 mg/kg), was given first, followed by a low dose of 2.5 mmol/kg (1320 mg/kg). This low dose is approximately 3.3 times that of the highest dose given in characterization of Sulfanegen-TEA which is 0.73 mmol/kg (393 mg/kg). Increasing doses were given from the lowest dose until LD50. The first increased dose of 3.6 mmol/kg (1939 mg/kg) achieved that goal. Death when it occurred was within 5 min of the injections. The mice were watched closely for two hrs following the injections and then checked daily for one week.
- Example 5 Swine cyanide models for IM treatment with sulfanegen.
- Figure 8a and 8b depict the swine cyanide models for IM treatment with sulfanegen TEA.
- Figure 8a depicts cyanide levels in placebo (control) and sulfanegen TEA treated animals while Figure 8b depicts lactate levels in placebo (control) and sulfanegen TEA treated animals.
- Two of the piglets treated with CN and sulfanegen TEA had a brief increase in lactate during recovery but lactate levels returned to baseline levels during the recovery.
- Piglets (n 2) treated with sulfanegen TEA (200 nig/kg) and no cyanide demonstrated normal blood chemistry and normal behavior.
- the eluate was treated with a solution of the desired amine (1.40 mmol) in H 2 0 (15 mL), and the resulting solution was allowed to stir at room temperature for 10 min. The solution was subsequently lyophilized to yield a white solid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides salts of sulfanegen and methods for their use.
Description
CYANIDE ANTIDOTES
Cross-reference to Related Applications
This patent application claims the benefit of priority of U.S. application serial No.
61/327,378, filed April 23, 2010, which application is herein incorporated by reference.
Statement of Government Support
This invention was made with government support under grant numbers 5U01- NS058087 and 3U54-NS063718 awarded by the National Institutes of Health. The government has certain rights in the invention.
Background
Currently available cyanide antidotes must be administered via intravenous (IV) administration. Sulfanegen sodium can be an effective cyanide antidote when administered via an intraperitoneal (IP) injection.
(Also, see, e.g, WO 2008/005806 and Cooper et ah, Journal of Biological Chemistry, 257, 816- 826 (1982).) However, this salt of sulfanegen is not sufficiently water soluble for effective intramuscular (IM) administration. Thus, in a mass casualty setting such as a terrorist attack or a major chemical accident, large numbers of cyanide-exposed victims are likely to be untreated in any rescue attempts using currently-available cyanide antidotes. Therefore, there is a need for cyanide antidotes amenable to more rapid delivery methods, such as via an autoinjector. Ideally, larger doses of antidote should be administered rapidly for maximal efficacy, inflammation at the site of administration should be minimal, and the antidote should be highly water soluble.
Summary of Certain Embodiments of the Invention
The present invention , as described herein, provides salts of sulfanegen including triethanolamine (TEA), diethanolamine (DEA), monomethylaminoethanol (MMAE) and dimethylaminoethanol (DMAE) salts that are significantly more water soluble than the sodium salt of sulfanegen. Accordingly, these new forms of sulfanegen are useful as cyanide antidotes. These new forms are effective when administered by injection (e.g. , IM or IV or IP) as well as when administered orally, and are inexpensive and rapidly acting, e.g., when administered by IM injection.
Brief Description of the Figures
Figure 1 depicts the effects of sulfanegen TEA 5 min post cyanide exposure.
Figure 2 depicts the effects of sulfanegen TEA 10 min post cyanide exposure.
Figure 3 depicts the effects of sulfanegen TEA 20 min post cyanide exposure.
Figure 4 depicts the effects of sulfanegen TEA 30 min post cyanide exposure.
Figure 5 depicts the effects of sulfanegen TEA 40 min post cyanide exposure.
Figure 6 depicts the effects of sulfanegen TEA vs FDA approved antidotes in the mouse model. CN = first column, H = second column, N/T = third column, sulfanegen sodium = fourth column. CN = cyanide treatment controls (no drug); H = hydroxocobalamin; N/T = combination of sodium nitrite and sodium thiosulfate.
Figure 7 depicts the changes in OxyHb and DeoxyHb in response to cyanide and antidote treatment (IM) in rabbit model.
Figures 8a and 8b depict the cyanide levels and lactate levels in the swine cyanide models for IM treatment with sulfanegen TEA.
Detailed Description
Accordingly, certain embodiments provide a triethanolamine, diethanolamine, monomethylaminoethanol or dimethylaminoethanol salt of a compound of the formula
In certain embodiments the invention provides a triethanolamine (TEA) or
diethanolamine (DEA) salt of a compound of the formula
wherein X+ is TEA or DEA in protonated form.
Certain embodiments rovide a salt of the following formula
wherein X+ is triethanolamine, diethanolamine, monomethylaminoethanol or
dimethylaminoethanol in protonated form.
In certain embodiments, the salt is a TEA salt.
In certain embodiments, the salt is a DEA salt.
In certain embodiments, the salt is a monomethylaminoethanol or dimethylaminoethanol salt.
Certain embodiments of the invention provide a salt of the following formula
wherein X+ is melamine, glucosamine, ethanolamine, tromethamine, N-methylaminoethanol and Ν,Ν-dimethy laminoethanol .
Certain embodiments provide a pharmaceutical composition comprising a salt as described herein and a pharmaceutically acceptable carrier.
In certain embodiments, the composition is adapted for intramuscular (IM)
administration.
In certain embodiments, the composition is adapted for intravenous (IV) administration. In certain embodiments, the composition is adapted for oral administration.
In certain embodiments, the composition is in unit dosage form.
In certain embodiments, the composition comprises about 1-10 grams (e.g., about 3-8 grams) of the salt.
In certain embodiments, the composition comprises about 1-12 grams of the salt.
Certain embodiments provide a method of treating cyanide poisoning in a subject in need of such treatment, comprising administering to a subject a therapeutically effective amount of the salt as described herein, or the composition as described herein.
In certain embodiments, the salt or composition is administered intramuscularly (IM).
In certain embodiments, the salt or composition is administered intravenously (IV).
In certain embodiments, the salt or composition is administered orally.
Certain embodiments provide a salt as described herein for use in therapy.
Certain embodiments provide a salt as described herein for use in treating cyanide poisoning.
Certain embodiments provide a salt as described herein for use in medical treatment or diagnosis.
Certain embodiments provide the use of a salt as described herein to prepare a medicament useful for treating cyanide poisoning in an animal.
Thus, the present salts may be administered, e.g. , IM, IV, or orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic
administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should generally contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained. The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules
may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non- toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.
The active compound may also be administered intravenously (IV), intraperitoneally (IP), or intramuscularly (IM) by infusion or injection, e.g., using an autoinjector. The compounds may be administered using an autoinjector. Solutions of the active compound can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. The ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum
drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
Useful dosages of the compounds can be determined, e.g., by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
Compounds of the invention can also be administered in combination with other therapeutic agents, for example, other agents that are useful for the treatment of cyanide exposure. Accordingly, in one embodiment the invention also provides a composition comprising sulfanegen TEA and/or sulfanegen DEA, at least one other therapeutic agent, and a pharmaceutically acceptable diluent or carrier.
The invention also provides a kit comprising sulfanegen TEA and/or sulfanegen DEA, packaging material, and instructions for administration. The kit may also contain at least one other therapeutic agent.
Scheme 1 illustrates a synthesis that that was used to prepare salts of sulfanegen including compounds of the invention. Scheme 1 illustrates the synthesis of salts in the ratio of about 2 : 1 (M+ : compound 3). The invention also includes other salt ratios, including but not limited to ratios of about 1 : 1. The invention also includes other physical forms (e.g.
complexes) of M+ and compound 3 including but not limited to cocrystals.
Scheme 1
Reagents and conditions for the synthesis of Scheme 1 : (a) 2 molar equivalent NaHS, ethanol; (b) Dowex-50WX8, FT form; (c) 2 equivalent of a biocompatible amine (M).
Accordingly, the present invention also includes salts of sulfanegen wherein the salt is melamine (4a), glucosamine (4b), ethanolamine (4c), tromethamine (4f), N-methylaminoethanol (4g) and Ν,Ν-dimethylaminoethanol (4h).
The invention will now be illustrated by the following non-limiting Examples.
Example 1. Water solubility of sulfanegen salts
The exchange of sodium in sulfanegen sodium with pharmaceutically acceptable amines provided the salts as depicted below and in Scheme 1 and Scheme 2. Surprisingly, both TEA and DEA sufficiently improved the aqueous solubility and physical characteristics (see Table 1). There was no structure activity relationship between the salt formulations and solubility.
Other unexpected results include the solubility of the monomethylaminoethanol
(MMAE) salt and the dimethylaminoethanol (DMAE). The choline salt of sulfanegen had a solubility of 1.2 M in water while the ethanolamonium salt, had a solubility of 1.39 M in water. Surprisingly, the solubility of the monomethylaminoethanol (MMAE) salt was three-fold higher than the choline salt and the dimethylaminoethanol (DMAE) salt gave an approximate four-fold increase in aqueous solubility. These amines are all aminoethanol derivatives differing only in methylation of the amino moiety. The solubility of their sulfanegen salts however did not follow a predictable pattern.
The efficacy of cyanide antidotes was measured as follows. A dose less than the LD50 was administered. This causes 'knock-down' or loss of neuromuscular coordination. The efficacy of antidote was measured by reduction in time for the animal to recover neuromuscular coordination. Swiss albino male mice were treated with cyanide (ip) at a dose that requires 60- 70 min for recovery. Briefly, the 'knocked-down' animal was placed on a wire mesh and inverted. The time for the animal to right itself to the top of the wire mesh screen was measured as the recovery time and the antidotal efficacy is measured as the reduction of this recovery time vs. the cyanide alone animals. Statistically this is much more powerful than LD50. As depicted in Figures 1, 2, 3, 4 or 5 sulfanegen TEA, administered IM or IP, is an effective cyanide antidote. Figure 6 depicts the effects of sulfanegen TEA vs FDA approved antidotes in the mouse model.
Example 3: Rabbit efficacy.
Figure 7 depicts the changes in OxyHb and DeoxyHb in response to cyanide and antidote treatment (IM) in rabbit model. Rapid recovery was demonstrated in the treated animals.
Example 4: Toxicity study of sulfanegen salts
Sulfanegen-TEA was dissolved in sterile saline and the dose administered in two injections, one in each leg muscle. There were four mice per group and three groups. A high dose of 8.9 mmol/kg (4789 mg/kg), was given first, followed by a low dose of 2.5 mmol/kg (1320 mg/kg). This low dose is approximately 3.3 times that of the highest dose given in characterization of Sulfanegen-TEA which is 0.73 mmol/kg (393 mg/kg). Increasing doses were given from the lowest dose until LD50. The first increased dose of 3.6 mmol/kg (1939 mg/kg) achieved that goal. Death when it occurred was within 5 min of the injections. The mice were watched closely for two hrs following the injections and then checked daily for one week.
All injections were bilateral in the thigh leg muscle, IM. The volumes did not exceed 60μ1 per leg muscle injection. Phosphate buffered saline kept the sulfanegen salt solutions within a 7.5-8.5 pH range. None of the animals showed signs of discomfort at the time of the injections. The Sulfanegen Na salt went into solution by heating with hot tap water and repeated vortexing. The volumes injected for the Sulfanegen sodium salt were greater than the other more soluble Sulfanegen salts. Each group was an n of four mice. At post injection 24 hours, all surviving animals passed the Righting Reflex Recovery within one minute and exhibited normal behaviors.
Example 5: Swine cyanide models for IM treatment with sulfanegen.
Figure 8a and 8b depict the swine cyanide models for IM treatment with sulfanegen TEA. Figure 8a depicts cyanide levels in placebo (control) and sulfanegen TEA treated animals while Figure 8b depicts lactate levels in placebo (control) and sulfanegen TEA treated animals.
Piglets treated with CN and no antidote (n= 4) died while piglets treated with CN and sulfanegen TEA (320 mg/kg, iv) all survived (n = 4) with normal blood chemistry. Two of the piglets treated with CN and sulfanegen TEA had a brief increase in lactate during recovery but lactate levels returned to baseline levels during the recovery. Piglets treated with CN (iv) and sulfanegen TEA (im) all survived (n = 5).
Piglets (n = 2) treated with sulfanegen TEA (200 nig/kg) and no cyanide demonstrated normal blood chemistry and normal behavior. Anesthetized piglets (n = 2) treated with triethanolamine hydrochloride (138 mg/kg, iv) demonstrated normal blood chemistry after recovery, however, a temporary increase in lactate was observed.
Example 6: Preparation of compounds 4a - 4h
General procedure for the preparation of compounds 4a-4h.
A solution of disodium 2,5-dihydroxy-l,4-dithiane-2,5-dicarboxylic acid tetrahydrate (prepared by the method of WO2008/005806) (0.25 g, 0.70 mmol) in H20 (7 mL) was applied to a column of ion-exchange resin Dowex 50WX8-200 (H ; 3 mL, 5 meq), and was eluted with H20 until the eluate tested negative for the presence of dithiane by KMn04 stain on TLC silica plate to provide compound 3 in solution. The eluate was treated with a solution of the desired amine (1.40 mmol) in H20 (15 mL), and the resulting solution was allowed to stir at room temperature for 10 min. The solution was subsequently lyophilized to yield a white solid.
Characterization data for 2,5-dihydroxy- 1 ,4-dithiane-2,5-dicarboxylic acid (3). Yield
99%. *H NMR (300 MHz, D20): δ 3.01 (2H, d, J= 14.4 Hz, major isomer), 3.21 (2H, d, J= 14.4 Hz, minor isomer), 3.45 (2H, d, J= 14.4 Hz, minor isomer), 3.90 (2H, d, J= 14.4 Hz). 13C NMR (75 MHz, D20): δ 35.2, 37.3, 76.0, 78.8, 174.5, 174.7. Anal. Calcd for C6H806S2: C, 30.00; H, 3.36; S, 26.69. Found: C, 30.12; H, 3.44; S, 26.48.
Compound 4a:
2.5-Dihydroxy-l,4-dithiane-2,5-dicarboxylic acid, bis-((2R,3R,4R,5S)-6- methylaminohexane-l,2,3,4,5-pentol) trihydrate salt (4a). Compound 4a was prepared by the general procedure of Example 6 in 99% yield. lU NMR (600 MHz, D20): δ 2.79 (6H, s), 2.83 (2H, d, J= 14.4 Hz, major isomer), 3.09 (2H, d, J= 14.4 Hz, minor isomer), 3.18-3.27 (5H, m), 3.58 (2H, d, J= 14.4 Hz, minor isomer), 3.65-369 (5H, m), 3.76-3.79 (2H, m), 3.82-3.84 (2H, m), 3.87 (2H, d, J= 14.4 Hz, major isomer), 4.10-4.13 (2H, m). 13C NMR (150 MHz, D20): δ 32.96, 35.92, 51.07, 62.64, 68.03, 70.51, 70.66, 70.87, 77.03, 176.84. Anal. Calcd for
C20H42N2O16S2-3H2O: C, 35.08; H, 7.07; N, 4.09; S, 9.37. Found: C, 34.94; H, 6.87; N, 4.00; S, 9.67. mp: 1 19-120 °C (dec).
Compound 4b:
2,5-Dihydroxy- 1 ,4-dithiane-2,5-dicarboxylic acid, bis-((3i?,4J?,5S)-3-Amino-6- (hydroxymethyl)-oxane-2,4,5-triol) salt (4b). Compound 4b was prepared by the general procedure of Example 6 in 99% yield. lU (600 MHz, D20): δ 2.86 (d, 2H, major isomer), 3.02 (m, 1H), 3.10 (d, 2H, minor isomer), 3.32 (dd, 1H), 3.48-3.55 (m, 3H), 3.58 (d, 2H, minor isomer), 3.68-3.71 (m, 1H), 3.75-3.82 (m, 2H), 3.87 (d, 2H, major isomer), 3.90-3.94 (m, 4H), 4.96 (d, 1H), 5.46 (s, 1H). Anal. Calcd for CjgK^^O^S^l.S H20: C, 34.56; H, 5.96; N,
4.48; S, 10.25. Found C, 34.65; H, 6.01; N, 4.47; S, 10.20. mp: 126-128 °C. Compound 4c:
2.5-Dihydroxy-l,4-dithiane-2,5-dicarboxylic acid, bis-(2-aminoethanol) salt (4c).
Compound 4c was prepared by the general procedure of Example 6 in 99% yield. Ή NMR (600 MHz, D20): δ 2.86 (2H, d, J= 14.4 Hz, major isomer), 3.10 (2H, d, J= 14.4 Hz, minor isomer), 3.15 (4H, t, J= 4.8 Hz), 3.57 (2H, d, J= 14.4 Hz, minor isomer), 3.83 (4H, t, J= 4.8 Hz), 3.86 (2H, d, J= 14.4 Hz, minor isomer). 13C NMR (150 MHz, D20): δ 35.94, 41.26, 57.59, 77.04, 176.78. Anal. Calcd for C10H22N2O7S2 .8H2O: C, 31.87; H, 6.31 ; N, 7.43; S, 17.02. Found: C, 31.91; H, 6.39; N, 7.32; S, 17.1 1. mp: 73-75 °C.
Compound 4d:
2.5-Dihydroxy-l,4-dithiane-2,5-dicarboxylic acid, bis-(2,2'-iminodiethanol) salt (4d).
Compound 4d was prepared by the general procedure of Example 6 in 99% yield. 1H NMR (600 MHz, D20): δ 2.85 (2H, d, J= 14.4 Hz, major isomer), 3.10 (2H, d, J= 14.4 Hz, minor isomer), 3.26 (8H, t, J= 4.8 Hz), 3.57 (2H, d, J= 14.4 Hz, minor isomer), 3.86 (2H, d, J= 14.4 Hz, minor isomer), 3.89 (8H, t, J= 4.8 Hz). 13C NMR (150 MHz, D20): δ 35.95, 48.87, 56.46, 77.03, 176.79. Anal. Calcd for C10H3oN2010S2: C, 37.32; H, 6.71 ; N, 6.22; S, 14.23. Found: C, 37.50; H, 6.68; N, 6.20; S, 14.16. Elucidation of structure via X-Ray crystallography. Crystals were grown from MeOH/Et20. mp: 104-105 °C.
Compound 4e:
2,5-Dihydroxy- l,4-dithiane-2,5-dicarboxylic acid, bis-(2,2',2"-nitrilotriethanol) salt (4e).
Compound 4e was prepared by the general procedure of Example 6 in 99% yield. ^H NMR (600 MHz, D20): δ 2.87 (2H, d, J= 14.4 Hz, major isomer), 3.11 (2H, d, J= 14.4 Hz, minor isomer),
3.52 (12H, t, J= 5.4 Hz), 3.60 (2H, d, J= 14.4 Hz, minor isomer), 3.89 (2H, d, J= 14.4 Hz), 3.99 (12H, t, J= 5.4 Hz). 13C NMR (150 MHz, D20): δ 36.6, 55.6, 55.9, 77.6, 177.4. Anal. Calcd for C^^g^O^: C, 40.14; H, 7.1 1; N, 5.20; S, 11.91. Found: C, 39.84; H, 7.18; N,
5.32; S, 11.63. Mp: 122-123 °C.
Compound 4f:
2,5-Dihydroxy-l ,4-dithiane-2,5-dicarboxylic acid, bis-(2-amino-2-hydroxymethyl- propane-l,3-diol) salt (4f). Compound 4f was prepared by the general procedure of Example 6 in 99% yield. lH NMR (D20): δ 2.84 (d, J = 14.1 Hz, 2H), 3.73 (s 12H) 3.85 (d, J = 14.1 Hz, 2H), 13C NMR (D20): δ 36.5, 59.9, 62.0, 77.6, 177.6, Anal. Calcd for C 31.34%, H 6.76%, N 5.22%, Found C 31.63%, H 6.56%, N 5.26%, mp 125.5-127 °C (dec).
Compound 4g:
2.5-Dihydroxy-l,4-dithiane-2,5-dicarboxylic acid, bis-[(2-methylamino)ethanol] salt (4g). Compound 4g was prepared by the general procedure of Example 6 in 99% yield. 1H NMR (600 MHz, D20): δ 2.77 (6H, s), 2.86 (2H, d, J= 14.4 Hz, major isomer), 3.10 (2H, d, J= 14.4 Hz, minor isomer), 3.20 (4H, t, J= 5.4 Hz), 3.58 (2H, d, J= 14.4 Hz, minor isomer), 3.86 (4H, t, J= 5.4 Hz), 3.88 (2H, d, J= 14.4 Hz, major isomer). 13C NMR (150 MHz, D20): δ 32.58,35.94, 50.46, 56.39, 77.04, 114.15, 176.81. Anal. Calcd for C12H26N208S2: C, 36.91 ; H, 6.71 ; N, 7.17; S, 16.42. Found: C, 36.75; H, 6.77; N, 7.16; S, 16.31. mp: 101-103 °C.
Compound 4h:
2.5-Dihydroxy-l,4-dithiane-2,5-dicarboxylic acid, bis-[(2-dimethylamino)ethanol] salt (4h). Compound 4h was prepared by the general procedure of Example 6 in 99% yield. 1H NMR (600 MHz, D20): δ 2.85 (2H, d, J= 14.4 Hz, major isomer), 2.94 (12H, s), 3.09 (2H, d, J = 14.4 Hz, minor isomer), 3.31 (4H, t, J= 5.4 Hz), 3.57 (2H, d, J= 14.4 Hz, minor isomer), 3.86 (2H, d, J= 14.4 Hz, major isomer), 3.91 (4H, t, J= 5.4 Hz). 13C NMR (150 MHz, D20): δ 35.98, 42.74, 55.17, 58.75, 77.05, 176.76. Anal. Calcd for C14H3oN208S2: C, 40.18; H, 7.22; N, 6.69; S, 15.32. Found: C, 40.07; H, 7.25; N, 6.67; S, 15.29. mp: 121-122 °C.
All publications, patents and patent applications cited herein are incorporated herein by reference. While in the foregoing specification this invention has been described in relation to
certain embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention.
The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising,"
"having," "including," and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to") unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein.
Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any
combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims
1. A triethanolamine, diethanolamine, monomethylaminoethanol or dimethylaminoethanol salt of a compound of the formula
2. The salt of claim 1 wherein the salt is a triethanolamine or diethanolamine salt.
3. The salt of claim 1 wherein the salt is a monomethylaminoethanol or
dimethylaminoethanol salt.
4. The salt of claim 1, which is a salt of the following formula
dimethylaminoethanol in protonated form.
5. The salt of claim 1 , which is a salt of the following formula
6. The salt of claim 1 or claim 5, which is a triethanolamine salt.
7. The salt of claim 1 or claim 5, which is a diethanolamine salt.
8. A pharmaceutical composition comprising a salt as described in any one of claims 1 -7 and a pharmaceutically acceptable carrier.
9. The composition of claim 8 that is adapted for intramuscular (IM) administration.
10. The composition of claim 8 that is adapted for intravenous (IV) administration.
11. The composition of claim 8 that is adapted for oral administration.
12. The composition of any one of claims 8-1 1 that is in unit dosage form.
13. The composition of claim 12 that comprises about 1-12 grams of the salt.
14. The composition of claim 12 that comprises about 3-8 grams of the salt.
15. A method of treating cyanide poisoning in a subject in need of such treatment, comprising administering to a subject a therapeutically effective amount of the salt of any one of claims 1-7, or the composition of any one of claims 8-14.
16. The method of claim 15, wherein the salt or composition is administered intramuscularly
(IM)
17. The method of claim 15, wherein the salt or composition is administered intravenously
(IV) 18. The method of claim 15, wherein the salt or composition is administered orally.
19. A salt according to any one of claims 1-7 for use in therapy.
20. A salt according to any one of claims 1 -7 for use in treating cyanide poisoning.
21. A salt as described in any one of claims 1 -7 for use in medical treatment or diagnosis.
22. The use of a salt as described in any one of claims 1-7 to prepare a medicament useful for treating cyanide poisoning in an animal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32737810P | 2010-04-23 | 2010-04-23 | |
US61/327,378 | 2010-04-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011133893A2 true WO2011133893A2 (en) | 2011-10-27 |
WO2011133893A3 WO2011133893A3 (en) | 2012-04-05 |
Family
ID=44834834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/033619 WO2011133893A2 (en) | 2010-04-23 | 2011-04-22 | Cyanide antidotes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011133893A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015157750A1 (en) * | 2014-04-11 | 2015-10-15 | Sam Houston State University | Formulations of dimethyl trisulfide for use as a cyanide antidote |
WO2015157752A1 (en) * | 2014-04-11 | 2015-10-15 | Sam Houston State University | Dialkyl trisulfides and formulations of dialkyl trisulfides for use as a cyanide antidote |
US9375407B2 (en) | 2014-04-11 | 2016-06-28 | Sam Houston State University | Dimethyl trisulfide as a cyanide antidote |
US11925623B2 (en) | 2020-07-21 | 2024-03-12 | Regents Of The University Of Minnesota | Methods for the treatment of conditions related to hydrogen sulfide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008005806A2 (en) * | 2006-06-30 | 2008-01-10 | Regents Of The University Of Minnesota | Therapeutic methods, compositions, and compounds |
-
2011
- 2011-04-22 WO PCT/US2011/033619 patent/WO2011133893A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008005806A2 (en) * | 2006-06-30 | 2008-01-10 | Regents Of The University Of Minnesota | Therapeutic methods, compositions, and compounds |
Non-Patent Citations (2)
Title |
---|
A J COOPER, M T HABER, AND A MEISTER: 'On the chemistry and biochemistry of 3-mercaptopyruvic acid, the alpha-keto acid analog of cysteine' THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 257, no. 2, 1982, pages 816 - 826 * |
HERBERT T. NAGASAWA, ET AL.: 'Novel, Orally Effective Cyanide Antidotes' JOURNAL OF MEDICINAL CHEMISTRY vol. 50, no. 26, 2007, pages 6462 - 6464 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015157750A1 (en) * | 2014-04-11 | 2015-10-15 | Sam Houston State University | Formulations of dimethyl trisulfide for use as a cyanide antidote |
WO2015157752A1 (en) * | 2014-04-11 | 2015-10-15 | Sam Houston State University | Dialkyl trisulfides and formulations of dialkyl trisulfides for use as a cyanide antidote |
US9375407B2 (en) | 2014-04-11 | 2016-06-28 | Sam Houston State University | Dimethyl trisulfide as a cyanide antidote |
US9456996B2 (en) | 2014-04-11 | 2016-10-04 | Sam Houston State University | Formulations of dimethyl trisulfide for use as a cyanide antidote |
US11925623B2 (en) | 2020-07-21 | 2024-03-12 | Regents Of The University Of Minnesota | Methods for the treatment of conditions related to hydrogen sulfide |
Also Published As
Publication number | Publication date |
---|---|
WO2011133893A3 (en) | 2012-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2458996B1 (en) | Novel oral forms of a phosphonic acid derivative | |
EP3056200B1 (en) | Huperzine for use in treating seizure | |
WO2018096504A1 (en) | Cbd prodrugs, compositions, and methods of administering cbd and cbd prodrugs | |
RU2600986C2 (en) | Azilsartan organic amine salts, method for their production and use | |
US9738669B2 (en) | Pentaaza macrocyclic ring complexes possessing oral bioavailability | |
US9156826B2 (en) | Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration | |
WO2011133893A2 (en) | Cyanide antidotes | |
US20210206713A1 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
US6194459B1 (en) | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants | |
AU2011232341B2 (en) | Improved stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone | |
IE891908L (en) | Novel esters | |
US20110224245A1 (en) | Treatment Of Neurological Disorders Using Huperzine | |
US8722706B2 (en) | Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts | |
JPH0269417A (en) | Schizophrenia treatment composition | |
CN103772245A (en) | Substituted L-cysteine compound, as well as preparation method and use thereof | |
WO2016168118A1 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
CN112939896B (en) | Biquaternary ammonium compound and preparation method and application thereof | |
KR102475176B1 (en) | Intravenous antiviral treatments | |
US20090275654A1 (en) | Pharmaceutical Gallium Compositions and Methods | |
JPH06501032A (en) | pharmaceutical composition | |
JP2009538822A5 (en) | ||
KR20160146689A (en) | Composition comprising a dopamine agonist and an l-dopa derivative for treating parkinson's disease | |
ES2732865T3 (en) | Antimicrobial compositions with effervescent agents | |
US20030065035A1 (en) | Novel stilbene derivative crystal and method for producing the same | |
CN112851599B (en) | Compound with biscationic quaternary ammonium salt structure, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11772787 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11772787 Country of ref document: EP Kind code of ref document: A2 |